Navigation Links
Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session
Date:11/17/2010

ent over the current best standard of care available in the USA. We are now well positioned to advance RVX-208 to the next clinical trial having witnessed the substantial and consistent elevation of HDL by ApoA-I production; which strongly indicates that RVX-208 should remove unwanted plaque from the arterial wall which is our main goal."

Resverlogix Senior Vice President of Medical Affairs Dr. Jan Johansson stated, "In patients who received the newer class of statins and had baseline HDL below 45mg/dL, an important high-risk subpopulation, the middle dose of 200 mg saw the most pronounced increases of 12% in ApoA-I (p<0.002), 21% in HDL cholesterol (p<0.015) and 32% in large particle HDL (p<0.018). We are delighted by these results and now have a much better understanding of what doses to use and what patient population to target moving forward in our ASSURE Phase 2b trial." 

An additional presentation at the AHA meeting was given by Dr. Norman Wong, Chief Scientific Officer of Resverlogix, containing new data detailing the effects of RVX-208 in vivo. The presentation was titled "RVX-208: An Orally Administrated Small Molecule Reduces Atherosclerosis in ApoE Null Mouse and Raises ApoA-I/HDL in Humans". In the ApoE null mice model of atherosclerosis, the oral administration of RVX-208 reduced aortic plaques in two separate models.  The presented model showed plaque reductions of up to 41%. Resverlogix to Host Webcast on ASSERT Phase 2 Trial Results - change in time
Resverlogix Corp. will host a live teleconference and webcast today at 2:15 pm Central/1:15 pm Mountain time. The purpose of the teleconference is to discuss the top line results of the Company's Phase 2 clinical trial (ASSERT) for RVX-208. The dial-in numbers for this event are toll free 1-800-319-4610 and international 1-604-638-5340. A link for this webcast will be posted onto the homepage of Resverlogix's website and can be accessed from the following addre
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data
2. Resverlogix Appoints Kenneth J. Zuerblis to Board of Directors
3. Resverlogixs Phase 2 ASSURE Trial Amended
4. Resverlogix Scientific Data Presented at EAS Congress
5. Resverlogix Completes Dosing for ASSERT Trial
6. Resverlogix Notice of Conference Call & Webcast for Year End Update
7. Resverlogix Activates First Site for ASSURE 1 Clinical Trial
8. Resverlogix Completes Patient Recruitment for ASSERT Trial
9. Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
10. Resverlogix Presenting at Biotech Showcase
11. Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... ROCKVILLE, Md. , May 4, 2015 /PRNewswire/ ... "RegeneRx") today announced that an independent team of ... have reported that Thymosin B4 (TB4) plays an ... dermal burn wounds, induced in an experimental mouse ... rapid vascular remodeling of damaged dermal tissue.  The ...
(Date:5/4/2015)... , May 4, 2015  Soligenix, Inc. (OTCQB: ... developing products that address unmet medical needs in the ... it will be presenting preclinical data from three of ... Defense Science and Technology Conference on May 12-14, 2015 ... at 701 Convention Plaza, St. Louis MO ...
(Date:5/4/2015)... May 4, 2015   Tocagen Inc. , ... data from Tocagen,s ongoing investigational studies were presented ... the American Association of Neurological Surgeons (AANS)/Congress of ... 1-2, 2015, in Washington, D.C. ... a meeting with FDA and continues to advance ...
(Date:5/4/2015)... Marianjoy Rehabilitation Hospital ... and hand impairments by acquiring the Armeo®Spring arm ... network site. , Secured through grant support of ... treatment option for patients with upper extremity weakness ... one of just four Illinois providers offering treatment ...
Breaking Biology Technology:Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing 2Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing 3Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 2Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 3Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 5Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 6Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 7Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 8Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 9Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 10Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 11Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 12Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2
... Genoptix, Inc.,(Nasdaq: GXDX ), a specialized laboratory services ... Life Sciences Conference,scheduled to take place at the Grand ... 2008., Douglas Schuling, Senior Vice President and CFO ... 22, beginning at,approximately 3:30 pm EDT. Mr. Schuling will ...
... of oil palm plantations will worsen the dual environmental ... are better protected, warn scientists in the most comprehensive ... Emily Fitzherbert from the Zoological Society of London and ... debate over the role of palm oil production in ...
... will likely be the move from today,s two-dimensional chips ... is now running at 1.4 gigahertz at the University ... Rochester chip is not simply a number of regular ... designed and built specifically to optimize all key processing ...
Cached Biology Technology:Genoptix Announces Participation at the UBS Global Life Sciences Conference 2Oil palm plantations are no substitute for tropical rainforests, a new study shows 2Oil palm plantations are no substitute for tropical rainforests, a new study shows 3First 3-D processor runs at 1.4 Ghz on new architecture 2
(Date:4/27/2015)... , Apr. 27, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... shipping to pre-order customers the first week of May, ... the month of May. Gino ... significant milestone for the company as Wocket® enters the ...
(Date:4/21/2015)... BURNABY, Canada , April 21, 2015 ... spending and evolving government policies are boosting access control ...   According to a recently published report ... & Opportunities, 2020 ", the access control systems market ... to nearly USD1.2 billion by 2020.The access control systems ...
(Date:4/20/2015)... April 20, 2015 The announcement ... Glenbeigh Records Management (GRM), Ireland,s ... Islamic Bank. Having built up an impressive track record of ... leading player within the records management sector in ... double is GCC staffbase and employ a further eight staff ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... oyster native to the West Coast could face a double ... research from the University of California, Davis, Bodega Marine Laboratory. ... Proceedings of the Royal Society B . Invasive snails ... snails were raised under ocean conditions forecast for the end ...
... Minn. , Jan. 15, 2014 MedNet Solutions ... study management systems, is pleased to announce that the latest ... released to the iMedNet user community.  iMedNet ... eClinical platform ideally suited to Sponsors and CROs wanting to ...
... news release is available in German . ... economists and politicians usually call a win-win situation: a relationship between ... acacia plants and the ants that live on them is an ... of food bodies and nectar as well as hollow thorns which ...
Cached Biology News:Acidification, predators pose double threat to oysters 2MedNet Solutions Announces Latest Release Of Its Innovative iMedNet EDC eClinical Solution 2Ants protect acacia plants against pathogens 2Ants protect acacia plants against pathogens 3
CASPR (H-66)...
Homo sapiens toll interacting protein Antigen: Recombinant Protein...
Human SIGIRR MAb (Clone 162201)...
... EPS 1001 Power Supply, 1. 1000 ... voltage, constant current, and constant power ... for precision and reproducibility.Stores and recalls ... flatbed gels on Multiphor II ...
Biology Products: